Strategic opportunities
- Clinical development and regional partnerships
- Scientific and biomarker collaboration
- Academic and investigator-initiated research
- Manufacturing and delivery-system expertise
- Capital-markets and corporate-development dialogue
Programs open for dialogue
The company has communicated interest in advancing BIV201 toward a pivotal program and continues development work around bezisterim. Any transaction depends on diligence, agreement and applicable disclosure requirements.
Start a conversation
Evidence and compliance note
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.